Novo Nordisk criticized for not disclosing payments to health groups, STAT says

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure to properly disclose payments to health and patient organizations over a seven-year period, Ed Silverman of STAT reports. In a 79-page report, the Prescription Medicines Code of Practice Authority, a self-regulatory panel overseen by the Association of the British Pharmaceutical Industry, found that “the circumstances of this case raised questions about the culture of the company and demonstrated poor governance and a lack of care in relation to the application of the disclosure processes,” citing evidence of “unreporting, inaccurate reporting and misreporting” the value of monetary transfers or “in-kind” payments to dozens of health care organizations, including professional medical associations, and patient groups between 2015 and 2022.